key: cord-1052866-h5rean9s
authors: Emilsson, Valur; Gudmundsson, Elias F.; Aspelund, Thor; Jonsson, Brynjolfur G.; Gudjonsson, Alexander; Launer, Lenore J.; Lamb, John R.; Gudmundsdottir, Valborg; Jennings, Lori L.; Gudnason, Vilmundur
title: Serum levels of ACE2 are higher in patients with obesity and diabetes
date: 2020-12-16
journal: Obes Sci Pract
DOI: 10.1002/osp4.472
sha: 98bbc47e508ae39de87b550fb789e0e42b8ca768
doc_id: 1052866
cord_uid: h5rean9s

OBJECTIVE: As severity of outcome in COVID‐19 is disproportionately higher among individuals with obesity, smokers, patients with hypertension, kidney disease, chronic pulmonary disease, coronary heart disease (CHD), and/or type 2 diabetes (T2D), serum levels of ACE2, the cellular entry point for the coronavirus SARS‐CoV‐2, were examined in these high‐risk groups. METHODS: Associations of ACE2 levels to smokers and patients with hypertension, T2D, obesity, CHD, or COPD were investigated in a single center population‐based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjavík Study (AGES‐RS) of the elderly (mean age 75 ± 6 years), using multiple linear regression analysis. RESULTS: Serum levels of ACE2 were higher in smokers and individuals with T2D and/or obesity while they were unaffected in the other patient groups. CONCLUSION: ACE2 levels are higher in some patient groups with comorbidities linked to COVID‐19 including obesity and T2D and as such may have an emerging role as a circulating biomarker for severity of outcome in the disease.

The current coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 SARS-CoV-2 interacts with the receptor ACE2, 2 to enter the host cell, binding the receptor with a 10-to 20-fold higher affinity than other SARS coronaviruses do. 3 COVID-19 is associated with major respiratory failure and greatest adverse outcomes from the disease are among the elderly, smokers, and/or individuals with an underlying disease including but not limited to coronary heart disease (CHD), hypertension, kidney disease, chronic pulmonary disease, type 2 diabetes (T2D), and obesity (body mass index, BMI > 30 kg/m 2 ). [4] [5] [6] [7] [8] [9] [10] While lower survival in COVID-19 might be attributed to the frailty and vulnerabilities of the high-risk patient groups mentioned above, other underlying factors could play role. For instance, variable levels and/or activity of the membrane bound receptor ACE2, 2 and its soluble counterpart, may contribute to this susceptibility. Just how the balance between the levels of soluble ACE2 and its membrane-bound receptor counterpart is maintained, has still to be fully defined. We postulate that SARS-CoV-2 infectivity may vary among individuals depending on their endogenous levels of circulating ACE2

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Estimated glomerular filtration rage (eGFR) was calculated from age, sex, and serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 12 Means and standard deviations were calculated for continuous characteristics and numbers and percentages for categorical characteristics.

Serum protein levels of ACE2 were measured in 5457 individuals from the AGES-RS using the slow-off rate modified aptamer Serum was prepared using a standardized protocol, 16 stored in 0.5 ml aliquots at À 80°C and serum samples that had not been previously thawed were used for the protein measurements. The order of sample collection and processing for protein measurements (4782 proteins measured including ACE2) were randomized and all samples run as a single set.

All SOMAmers that passed quality control had median intra-and inter-assay coefficient of variation (CV) less than 5% similar to that reported on variability in the SOMA scan assays. 17 Various metrics related to the performance of the proteomic platform were applied, including both direct assessment of aptamer specificity via tandem mass spectrometry analysis as well as inferential support using proteogenomics analysis, indicating consistent target specificity across the platform. 13 Hybridization controls were used to correct for systematic variability in detection and calibrator samples of three dilution sets (40%, 1%, and 0.005%) were included so that the degree of fluorescence was a quantitative reflection of protein concentration.

ACE2 was investigated on a log2 scale, where a one-unit increase represents a doubling in levels on the RFU scale. Multiple linear regression analysis was used to study the association between two or more independent variables (predictors) to a single continuous dependent variable (outcome). 18 In our case, the independent risk predictors included a priori selected set of comorbidities known to be associated with severity of outcome in COVID-19 (see Table 1 ), while the outcome variable was ACE2 levels in serum. Also, the model included adjustment for important confounding variables such as age and sex.

Results from multiple linear regression analysis with ACE2 levels (log2) as the outcome are highlighted in Table 1 showed higher ACE2 levels compared with those with no T2D or with normal glucose levels ( Table 1) . Serum levels were significantly increased in current smokers compared with individuals who never smoked (β ¼ 0.0299, p ¼ 0.018) and with sex (β ¼ À 0.0385, p < 0.001) ( Table 1 ). In contrast, ACE2 levels were not significantly associated with age, eGFR, COPD, hypertension, or CHD (Table 1 ).

The severity of outcome in COVID-19 is greatly influenced by various comorbidities and unhealthy lifestyle. [8] [9] [10] Higher circulating levels of ACE2 were observed in some of these groups including smokers and patients with obesity and/or T2D. The observation that 240 -

ACE2 levels are elevated in smokers agrees well with a study showing upregulation of ACE2 mRNA in the respiratory tract of smokers as well as rodents exposed to cigarette smoke. 19 Further, the finding that ACE2 levels are higher in both diabetics and those with impaired fasting glucose (Table 1) is of interest given recent reports showing that risk of critical admissions and mortality in COVID-19 is two to three times greater in patients with diabetes. 20, 21 There can be many reasons for the increased susceptibility to COVID-19 among the obese and diabetics including for instance impaired immune response in these patient groups. 22 However, the adipose tissue contains as many ACE2 receptors as pulmonary tissues, 23 and ACE2 expression in adipose tissue of mice is increased by high fat diet. 24 We postulate that higher circulating levels of ACE2 in patients with obesity and/or T2D may reflect increased abundance of the membrane bound ACE2 receptor and/or activity in solid tissues, that in turn may reflect higher viral load among these high-risk groups leading to increased susceptibility to adverse outcomes in COVID-19. Thus in addition to altered ACE2 levels, obesity and T2D are associated with chronic inflammation that can aggravate inflammation in pulmonary tissues, 25 which combined may influence the severity of outcome in COVID-19.

ACE2 is a membrane-bound ectoenzyme that is released into the circulation via ectodomain shedding. 26 Variable levels of ACE2 in serum are likely a result of genetic factors, differential gene expression, and/or ectodomain shedding influenced by disease or administration of drugs via negative or positive feedback loops of the renin-angiotensin system. 26 As proteins in circulation emanate from virtually every tissue of the body, 13 Phenotypes definitions are provided in Section 2. Age in years 76.6(5.6); 57.3% females; impaired fasting glucose 5.6-6.9 (n ¼ 1983); mean BMI 27.1 (4.4), T2D (n ¼ 660); hypertension (n ¼ 2739); ARBs users (n ¼ 753), ACEIs users (n ¼ 699); other antihypertensive users (n ¼ 1991); never smoker (n ¼ 2253), former smoker (n ¼ 2405), current smoker (n ¼ 655); CHD (n ¼ 1217); COPD (n ¼ 644); eGFR ml/min/1.73 m 2 ¼ 75.0 (17.3). b p-value from a F-test. EMILSSON ET AL.

The y-axis represents log2-transformed distribution of ACE2 levels in the serum while the x-axis shows different categories of BMI (kg/m 2 ), also expressed in Table 1 . The broken line (blue) going through the median in ACE2 levels of the lean group (BMI < 25), enables better comparison to the other BMI categories. The statistical significance of the comparison between individuals with overweight, obesity, or severe obesity to that of individuals who are lean was obtained from the multiple regression analysis presented in Table 1 

Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decadelong structural studies of SARS coronavirus

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A third of covid-19 patients admitted to UK hospitals die

OpenSAFELY: factors associated with COVID-19 death in 17 million patients

Obesity and impaired metabolic health in patients with COVID-19

Features of 20,133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area

Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -United States

Age, gene/environment susceptibility-Reykjavik study: multidisciplinary applied phenomics

A new equation to estimate glomerular filtration rate

Co-regulatory networks of human serum proteins link genetics to disease

Aptamer-based multiplexed proteomic technology for biomarker discovery

It's in our blood: a glimpse of personalized medicine

Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group

Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy

Multiple linear regression

Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -a systematic review, meta-analysis, and meta-regression

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

Aging, obesity, and inflammatory age-related diseases

Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms

ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet

Inflammation and metabolic disorders

From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension

Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy

How to cite this article: Emilsson V

Serum levels of ACE2 are higher in patients with obesity and diabetes